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Abstract 
Introduction: Diabetic individuals have several 
complications, such as diabetic retinopathy and 
nephropathy as well as an increased mortality risk and 
impairment in health-related quality of life. Despite 
some authors have suggested that pulmonary function 
reduction might be a chronic complication of Diabetes 
mellitus (DM), there are doubts whether the pulmonary 
function decrease is really caused by DM itself or if it 
represents a deleterious impact of ageing process. 
Aims: This study aimed to compare respiratory muscle 
strength and pulmonary function in diabetic and non-
diabetic elderly patients as well as to evaluate a 
possible correlation of this effect with glycemic control. 
Methods: For this case-control study, older adults (age 
over 60 years old) were randomly selected from an 
ageing study (EELO project) and they were separated 
in Diabetic (DG) and non-diabetic group (referred as 
control group, CG). Respiratory muscle strength was 
assessed by measuring maximum static inspiratory 
and expiratory pressures (MIP and MEP) using 
manovacuometer, while pulmonary function was 
evaluated by spirometry (considering the following 
variables: FVC, FEV1, FEV1/FVC).  All the variables  
 
 
 
were presented as % of predicted values, corrected for 
Brazilian population. 
Results: 255 older adults were enrolled at this study 
(85 diabetic and 170 non-diabetic patients). Diabetic 
individuals presented lower MIP (p=0.03), FVC 
(p=0.02) and FEV1 (p=0.02) when compared to non-
diabetic individuals. However, no differences were 
observed concerning MEP and FEV1/FVC between the 
groups. Positive correlations between glycemic control 
and FVC (rS: -0.14; p=0.02) and between glycemic 
control and FEV1 (RS: -0.16; p=0.01) were observed 
according to Sperman Correlation. 
Conclusion: According to these results, it can be 
concluded that diabetic patients show respiratory 
muscle weakness and decline of pulmonary function in 
comparison to non-diabetic individuals. Therefore, it 
can be suggested that pulmonary function evaluation 
should be recommended at the evaluation of diabetes’ 
chronic complications.   
Keywords: Elderly; Diabetes; Pulmonary function; 
Respiratory muscle strength. 
 
INTRODUCTION 
The type-2 Diabetes mellitus (DM) is a prevalent 
disease worldwide, affecting approximately 25% of the 
elderly population [1],  with a projection of about 300 
million adults by 2030 [2].  
DM patients have several complications, such as 
obesity, retinopathy and nephropathy [3] as well as an 
increased mortality risk and impairment in health-
related quality of life, representing high costs to health 
system [4]. Thus, creating effective policies towards the 
disease treatment is considered a challenge for public 
health system. 
Diabetic individuals also have higher muscle mass 
loss  [5] and reduced muscle strength as well as less 
tolerance to exercise when compared with non-diabetic 
patients [6-9]. 
Regarding respiratory muscle strength, clinical 
observation indicates that DM is associated with a 
higher risk of developing respiratory muscle weakness  
[7-9]. Recent studies with animal models showed that 
diabetes evokes severe damage to the diaphragmatic 
function, leading to a substantially reduced respiratory 
muscle capacity [10]. 
Besides, several studies have described an 
association of pulmonary function and DM [11-13]. 
There are evidences that the deterioration of glycemic 
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control is a strong determinant of reduced pulmonary 
function in type-2 diabetic patients [14,15].  
Additionally, Ljubic et al.[16] showed that diabetes 
presence could lead to pulmonary complications, due 
to collagen and elastin changes [17]. Therefore, 
despite some authors have suggested that pulmonary 
function reduction might be a chronic complication of 
DM, there are doubts whether the pulmonary function 
decrease is really caused by DM or if this represents a 
deleterious impact of ageing process. 
Thus, this study aimed to compare respiratory 
muscle strength and pulmonary function in diabetic and 
non-diabetic elderly patients as well as to evaluate a 
possible correlation of this effect with glycemic control.  
 
METHODS 
This study was approved by the University Research 
Ethics Committee (Protocol no. PP0063/09).  
Individuals were informed about the aims of the study 
and signed the informed consent prior to any 
methodological procedure. 
This case-control study followed the criteria 
established by Strengthening the Reporting of 
Observational Studies in Epidemiology – STROBE[18].   
The convenience sample consisted of older adults (age 
over 60, according to recommendations of World 
Health Organization for developing countries[19]) who 
participated on an interdisciplinary project (EELO 
Project - Study on ageing and longevity). The EELO 
Project is a thematic project developed at University of 
Northern Parana (UNOPAR) which aimed to evaluate 
the socio-demographic factors and indicators of health 
conditions of older adults in Londrina, a city of Northern 
Paraná, Brazil. The total sample of the EELO project 
consisted of 508 individuals, which is representative of 
the 43610 citizens older than 60 years living in 
Londrina. 
This study was developed in Londrina, a middle-
sized city from south region of Brazil since the elderly 
population of this city represents 12% of the total 
population with similar prevalence described in other 
developed countries [20,21].  
Individuals with type-2 DM who met International 
Classification and Diagnosis Standards for Diabetes 
classification[22] were included at the diabetic group 
(DG). Patients were classified as diabetic if they 
exhibited the following symptoms: polyuria, polydipsia 
and weigh loss associated with glycemia above 200 
mg/dl [23]. All patients were under proper medical 
treatment with oral antidiabetic drugs or insulin, as 
necessary. Moreover, health older individuals without 
diabetes were recruited as a control group (CG). 
Pulmonary diseases, thorax abnormalities, smoking 
history, cardiac insufficiency disease or treatment, 
respiratory infection over the last 30 days and previous 
or actual smoking were established as the exclusion 
criteria for this research. After analysis of eligibility 
criteria, 255 individuals were included (85 diabetic 
patients referred as the diabetic group and 170 non-
diabetic patients referred as the control group). 
Structured questionnaires were used to assess data 
regarding anthropometric and diseases characteristics 
and medication consumption.  
All blood samples were collected by peripheral vein 
puncture after 12-hour fasting. Fast glycemia was 
measured by colorimetric enzymatic methodology (Lab 
test kit) and glycated hemoglobin (HbA1c) through 
HPLC Biorad-D10 Hemoglobin Testing System. 
Diabetic patients were classified as controlled and 
uncontrolled diabetes, according to the value of 
glycated hemoglobin (Table 1). Glycated hemoglobin is 
a marker that reflects the glycemic control in a period 
from 8 to 12 weeks previously to the exam[24].  
 
 
 
 
 
 
 
 
 
The patients’ respiratory muscle strength was 
evaluated through the measure of the maximal 
inspiratory pressure (MIP) and maximal expiratory 
pressure (MEP) using the GERAR® analog 
manovacuometer (São Paulo, Brazil) featuring a -200 
to + 200 cmH2O scale, a capsule-type sensor and a 
spigot connection. The exams attended international 
standards established by the American Thoracic 
Society [25], previously described by Black and Hyatt 
[26]. There were performed at least 3 maneuvers, 
being 2 reproducible (difference lower than 10% 
between values). 
The highest value of respiratory muscle strength 
(MIP and MEP) found was used and expressed in 
percentage of predicted values (pred.) described for 
Brazilian population, according to the Neder et al [27]. 
Pulmonary variables (forced vital capacity (FVC), 
forced expired volume at the first second (FEV1), 
FEV1/FVC ratio) were measured by Pony-FX 
spirometer (COSMED, SRL, Rome, Italy).The exams 
attended international standards established by the 
American Thoracic Society and the European 
Respiratory Society [28]. 
Spirometry was performed at controlled temperature 
room. The subjects took a rest from 5 to 10 minutes 
before the test and during this period, they remained 
sited and using a nose clip. Before the procedure 
started, it was carefully described. The spirometer was 
computerized and printed the FEV1 and FVC values 
after the forced expiration had been performed. Best of 
three satisfactory readings was taken for the analysis. 
The highest value for FVC and FEV1 were used in the 
ratio FEV1/FVC. The variables were shown as the 
percent predicted values based on regression 
equations for Brazilian population [29]. 
GraphPad Prism 5.0 and G Power 3.0 were used for 
statistical analysis, setting the confidence interval in 
95% and 5% of the significance level (p<0,05) for all 
tests.  
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A pilot study was developed to calculate the sample 
size for testing the null hypothesis that there is no 
difference between MIP and the MEP and the 
pulmonary function between the diabetic and the non-
diabetic groups. The following statistic parameters 
were established (power test: 0.8 and p<0.05) and it 
was determined that the minimum needed sample for 
this research would be 56 diabetic patients and 112 
non-diabetic ones. 
Shapiro-Wilk test was used to evaluate whether the 
data had normal distribution. Considering that the 
variables used did not show normal distribution, all 
data were presented as median and interquartile range 
[25-75]. 
Mann-Whitney test was used to compare variables 
related to respiratory muscle strength MIP and MEP, 
as well as those related to pulmonary function (FVC, 
FEV1, FEV1/FVC) between the groups. Besides, 
Spearman Correlation was used to evaluate possible 
associations between glycemic control and the 
variables studied. 
 
RESULTS 
Initially, the study was composed by 455 individuals. 
However, 255 attended the eligibility criteria and 
composed the final sample (85 diabetic patients and 
170 control patients) and 200 older adults were 
excluded.  
The diabetic group had similar age (Mean: 
70.12±6.85) than the control one (Mean: 69.55±6.32), 
according to the Student t test (p=0.50). Both groups 
had similar anthropometric data expressed in table 2.  
 
 
 
 
 
 
 
 
 
 
 
 
Diabetic individuals presented lower MIP (DG: 81.9% 
pred.; Interquartile interval range: 71.2 – 110.3) when 
compared to non-diabetic individuals (CG: 95.2% pred; 
Interquartile range: 74.8 – 119.5), according to the 
Mann-Whitney test (p=0.03). 
There was no difference in the MEP of diabetic   
(DG: 102.8% pred; Interquartile interval: 80.5 – 130.8) 
and non-diabetic patients (CG: 108.9% pred; 
Interquartile interval: 89 – 137.1), according to the 
Mann-Whitney test (p=0.06). Data concerning 
inspiratory and expiratory muscle strength is shown in 
table 3. 
Forced vital capacity (FVC) was lower in diabetic 
individuals (GD: 75.5% pred; Interquartile interval:67.9 
– 86.9) when compared with non-diabetic ones (CG: 
82.63% pred; Interquartile interval: 73.6 – 94.2), 
according to the Mann-Whitney test (p=0.02). 
Forced expired volume at the first second (FEV1) 
was also lower in diabetic individuals (DG: 79.15% 
pred; Interquartile interval: 66.59 – 90.12), in relation to 
non-diabetic ones (CG: 85.36% pred; Interquartile 
interval: 71.74 – 97.06), according the Mann-Whitney 
test (p=0.02). 
The relation FEV1/FVC did not present meaningful 
differences between the diabetic and the non-diabetic 
group (DG: 103.1; Interquartile interval: 93.35 – 109.3 
versus GC: 102.2; Interquartile interval: 94.91 – 107.7), 
according to the Mann-Whitney test (p=0.45). Data 
concerning pulmonary function evaluation is also 
shown in table 4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DISCUSSION 
 
The present study provides strong evidence that the 
pulmonary function is impaired in type-2 diabetic 
individuals. Although it was observed a marked 
reduction of the MIP on the diabetic group, the same 
decline was not detected on MEP. These results may 
be  explained by the fact that abdominal muscles are 
known for their substantial contribution to the exhaling 
pressure, whilst inhaling pressure essentially depends 
on the diaphragm muscle [30,31]. Similarly, individuals 
with type-1 diabetes showed lower respiratory muscle 
strength [32,33] and decreased muscle endurance[34] 
in opposition to non-diabetic individuals. However, 
Kabitz et al.[15] did not verify changes in pulmonary 
function of type-2 diabetes patients. 
Despite there are some reports concerning 
peripheral muscular weakness in diabetic 
individuals[5;35;36], few studies investigated 
pulmonary function in such patients.  
The forced vital capacity (FVC) and the forced 
expired volume at the first second (FEV1) were lower in 
diabetic group in comparison to the non-diabetic one. 
These data are in agreement with previous studies [37-
41]. Despite the significant reduction of FVC and FEV1, 
it was not observed a statistically significant decline of 
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the relation FEV1/FVC (p=0.45), confirming previous 
reports[16;39]. 
Considering that DM induces metabolic and 
structural changes on skeletal muscles, many 
mechanisms may contribute to the occurrence of 
respiratory muscle weakness found in diabetic 
individuals. Indeed, DM causes metabolic changes 
characterized by reduced cellular glucose caption as 
well as oxidation of fatty acids and  structural changes, 
with muscular atrophy, increase of lipids stockage, as 
well as changes in muscle fibers [42]. 
Additionally, studies have shown that an 
increase of systemic inflammation associated to 
diabetes[35] could result in pulmonary inflammation[43] 
as well as causing wounds in the respiratory tract [35, 
44]. Besides, a decrease in respiratory defense 
mechanisms and an increase in the susceptibility to 
oxidative profile may result in subsequent loss of the 
pulmonary function[4]. Furthermore, it was 
demonstrated that pulmonary complication in diabetic 
patients are, partially, due to a narrowing in alveoli 
walls, alveolar capillaries and pulmonary arterioles [45, 
46]. 
Moreover, it is noteworthy that microvascular 
complications and hyperglycemia may occur by 
glycosylated pro-inflammatory protein formation [47]. 
Considering that the alveolar-capillary network consist 
of a large network, the lungs can be potentially affected 
by diabetic microangiopathy[48,49].  
There are evidences that pulmonary 
alterations, as well as muscle, renal and retina 
changes observed in diabetic patients are related to a 
poor glycemic control. In this context, Yeh et al.[40] 
reported that observed changes in FVC and FEV1 are 
related to the degree of hyperglycemia, diabetes’ 
duration and pharmacological treatment. 
The association of DM and the impaired 
pulmonary function may occur in a bidirectional way. 
Although various studies have reported pulmonary 
alterations as one of the chronic complications of DM, it 
was also observed that individuals with lower 
pulmonary function present risk of developing insulin 
resistance and type-2 diabetes. Besides, it was also 
observed that subjects with impaired result at 
spirometry tests presented higher risk for DM [7;11;35; 
50; 51]. 
It can be pointed as one of the study limitations 
the lack of evaluation of lung diffusion of carbon 
monoxide capacity (DCO) that may also be reduced in 
diabetic patients [40]. Furthermore, it may be 
highlighted that longitudinal studies should be 
performed to evaluate the pulmonary function in 
diabetic elderly. 
However, the novelty in this study was the 
assessment of respiratory muscle strength and 
pulmonary function at the same older individuals. In 
addition, changes in lung function were due to poor 
glycemic control of diabetes. 
From the results, it can be concluded that diabetic 
patients show respiratory muscle weakness (expressed 
through MIP) and decline of pulmonary function 
(expressed through FVC and FEV1 levels) in 
comparison to non-diabetic individuals. Additionally, it 
was also observed that the impairment in pulmonary 
function is related to glycemic control in physically 
independent elderly. 
Considering that DM is an important public 
health problem, with high prevalence and morbidity, it 
can be suggested that pulmonary function evaluation 
could be recommended at the evaluation of diabetes’ 
chronic complications.  
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